Reviewing Psyence Biomedical (NASDAQ:PBM) and Neuphoria Therapeutics (NASDAQ:NEUP)

Psyence Biomedical (NASDAQ:PBM – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Psyence Biomedical and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Psyence Biomedical and Neuphoria Therapeutics, as reported by MarketBeat.

Neuphoria Therapeutics has a consensus target price of $21.00, indicating a potential upside of 296.23%. Given Neuphoria Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Psyence Biomedical.

Insider and Institutional Ownership

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Psyence Biomedical has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.

Valuation & Earnings

This table compares Psyence Biomedical and Neuphoria Therapeutics”s revenue, earnings per share (EPS) and valuation.

Psyence Biomedical has higher earnings, but lower revenue than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Summary

Psyence Biomedical beats Neuphoria Therapeutics on 8 of the 12 factors compared between the two stocks.

About Psyence Biomedical

(Get Free Report)

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.